For over 50 years, the only available oral anticoagulants for the treatment and prevention of thromboembolic diseases have been vitamin K antagonists (VKA) such as warfarin. Although highly effective, VKAs have many disadvantages: they have a narrow therapeutic range with a subsequent need for frequent monitoring, a >10-fold interindividual variation in dose-response, and numerous interactions with drugs and food. Thus, antithrombotics have been developed, and they emerged to circumvent these problems and limitations.
- Oral anticoagulants
- Venous thromboembolic disease